

# Physician Education Express

Physician/Nurse Education - Inpatient Order Entry for All IV and PO Fluoroquinolones



**Audience:** Physicians, Residents, Nurse Practitioners, Physician Assistants, and Nurses  
**Education Level-** **Yellow**

August 18<sup>th</sup>, 2020

## Background/Rationale:

- Published literature supports the requirement of clinical indication at time of order entry to increase appropriate antimicrobial use.
- Indication at time of order entry is also recommended by the National Quality Partners (NPQ) and CDC.
- The FDA recommends reserving the use of fluoroquinolones for specific indications *“...when patients have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (Eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects)”*.
- ID Clinical Council endorses required indications for fluoroquinolone antibiotics to prompt provider and clinician assessment of antibiotic appropriateness.

### Which Antibiotics Are Indications Required for?

- CIPRofloxacin (IV/PO)
- LEVofloxacin (IV/PO)
- MOXifloxacin (IV/PO)

### Will an Indication be Defaulted in Current PowerPlans?

- Yes, when possible the indication corresponding to the order in current PowerPlans will be pre-populated.

### What If the Indication I am looking for Isn't Listed?

1. If your indication is not listed, that means that indication is not endorsed for fluoroquinolone use at IU Health. Consult your ID resources for antimicrobial alternatives.
2. If no alternatives exist select “Other” from the drop-down, and write indication in the comments field
  - Example: MOXifloxacin “Other” - Stenotrophomonas maltophilia

### Which Indication Options are Available to Choose from?

| Antibiotics   | Indication  |
|---------------|---|
| CIPRofloxacin | <ul style="list-style-type: none"> <li>• Prophylaxis</li> <li>• CF exacerbation</li> <li>• Bone/joint</li> <li>• Pseudomonas requiring Oral Treatment</li> <li>• Severe PCN/cephalosporin allergy</li> <li>• Febrile neutropenia (LOW-RISK)</li> <li>• Infectious diarrhea</li> <li>• Other (Please specify in comments)</li> </ul> |
| LEVofloxacin  | Pneumonia in Child < 40 kg<br>Other (Please specify in comments)  |
| MOXifloxacin  | Pneumonia<br>Severe PCN/cephalosporin allergy<br>Other (Please specify in comments)   |

## Highlights

**IU Health  
 System Go-Live:  
 August 18<sup>th</sup>,  
 2020**

### **Indications required for:**

- CIPRofloxacin (IV/PO)
- LEVofloxacin (IV/PO)
- MOXifloxacin (IV/PO)

When possible the indication corresponding to the order in current PowerPlans will be pre-populated. .









### **For further information:**

Contact the National Quality Partners (NPQ) and CDC.

## Example:






### PowerChart Order Entry

#### ▼ Details for CIPRofloxacin (Cipro)



|   |   |   |
|---|---|---|
|  <b>Details</b>  |  Order Comments  |  Diagnoses |
|    |   |   |
| *Dose: <input type="text" value="400"/>   | *Dose Unit: <input type="text" value="mg"/>   |   |
| Drug Form: <input type="text"/>   | *Frequency: <input type="text" value="Q12H"/>   |   |
| PRN Reason: <input type="text"/>  | *Indication: <input type="text"/>   |   |
| *Pharmacy May Convert to Oral Per Policy: <input type="text" value="Yes"/>  | *Start Date/Time:   |   |
| Duration Unit: <input type="text"/>   | Stop Type:  |   |
| This Field Currently Not in Use: <input type="text"/>   |   |   |

Bone/Joint  
CF Exacerbation  
Infectious Diarrhea  
Severe PCN/Cephalosporin Allergy  
Pseudomonas Requiring Oral Treatment  
**Febrile Neutropenia (LOW-RISK)**  
Prophylaxis  
Other (Please specify in comments)

### PowerChart Active Orders

|   |   | Order Name ▲  | Status  | Details  |
|---|---|---|---------|--|
|  |  |  CIPRofloxacin (Cipro) | Ordered | 400 mg, IVPB, Q12H, Indication: Febrile Neutropenia (LOW-RISK), 04/3 |

### MAR Summary

| Medications   |
|---|
| CIPRofloxacin   |
|  <br>CIPRofloxacin (Cipro)<br>400 mg, IVPB, Q12H, Indication: Febrile Neutropenia (LOW-RISK), 04/30/20 14:00:00 EDT, 200 mL/hr, Infuse Over 60 Minutes, Total Volume (mL) = 200 |
| CIPRofloxacin   |
| Dextrose 5% in Water  |

### Future Direction:

This feature will be expanded to other antimicrobial agents over time pending the clinical success of this initiative